Literature DB >> 24320947

Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry.

Ryu Matsuo1, Masahiro Kamouchi, Tetsuro Ago, Jun Hata, Yuji Shono, Junya Kuroda, Yoshinobu Wakisaka, Hiroshi Sugimori, Takanari Kitazono.   

Abstract

AIM: The present study aimed to determine the efficacy and safety of thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) therapy in older patients compared with younger patients.
METHODS: Using the Fukuoka Stroke Registry, a prospective multicenter study for acute stroke in Japan, we analyzed data of 401 patients with acute ischemic stroke (aged 74.5 ± 13.1 years) treated with thrombolytic therapy using rt-PA. Patients were categorized into two groups according to age: those aged ≥ 75 years (n=240) and <75 years (n=161). Neurological improvement was defined as a decrease in the National Institute of Health Stroke Scale (NIHSS) score of ≥ 4 during hospitalization or an NIHSS score of 0 at discharge. Good functional outcome was defined as a modified Rankin scale score of 0-2 at 3 months after onset.
RESULTS: Neurological symptoms at admission were more severe in older patients than in younger patients. Old age (≥ 75 years) was not associated with neurological deterioration (multivariate-adjusted odds ratio [OR] 0.90, 95% confidence interval [CI] 0.46-1.77), neurological improvement (multivariate-adjusted OR 0.91, 95% CI 0.54-1.53) and symptomatic intracranial hemorrhage (multivariate-adjusted OR 1.11, 95% CI 0.19-8.87). Old age was negatively associated with good functional outcome (multivariate-adjusted OR 0.29, 95% CI 0.16-0.52) and positively associated with in-hospital mortality (multivariate-adjusted OR 19.3, 95% CI 2.4-474.9).
CONCLUSIONS: In patients treated with rt-PA, old age is associated with poor functional outcome and in-hospital mortality. However, the probability of neurological improvement and symptomatic intracranial hemorrhage in older patients is comparable with that in younger patients.
© 2013 Japan Geriatrics Society.

Entities:  

Keywords:  aged; brain infarction; functional outcome; thrombolysis; tissue plasminogen activator

Mesh:

Substances:

Year:  2013        PMID: 24320947     DOI: 10.1111/ggi.12205

Source DB:  PubMed          Journal:  Geriatr Gerontol Int        ISSN: 1447-0594            Impact factor:   2.730


  6 in total

1.  Pretreatment with Danhong injection protects the brain against ischemia-reperfusion injury.

Authors:  Shaoxia Wang; Hong Guo; Xumei Wang; Lijuan Chai; Limin Hu; Tao Zhao; Buchang Zhao; Xiaoxu Tan; Feifei Jia
Journal:  Neural Regen Res       Date:  2014-08-01       Impact factor: 5.135

2.  Intravenous thrombolysis with recombinant tissue plasminogen activator for ischemic stroke patients over 80 years old: the Fukuoka Stroke Registry.

Authors:  Ryu Matsuo; Masahiro Kamouchi; Haruhisa Fukuda; Jun Hata; Yoshinobu Wakisaka; Junya Kuroda; Tetsuro Ago; Takanari Kitazono
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

3.  Neuroprotective Effect of Xueshuantong for Injection (Lyophilized) in Transient and Permanent Rat Cerebral Ischemia Model.

Authors:  Xumei Wang; Shaoxia Wang; Jinxin Wang; Hong Guo; Zhaopeng Dong; Lijuan Chai; Limin Hu; Yue Zhang; Hong Wang; Lu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-23       Impact factor: 2.629

4.  Effect of Danhong injection on neurological recovery and adverse events in patients with acute ischemic stroke: A protocol for a randomized, double-blind, placebo-controlled clinical study.

Authors:  Junfeng Gao; Xiangzhong Shao; YiXiang Guan; Juxiang Mei
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

5.  Pharmacological Mechanisms Underlying the Therapeutic Effects of Danhong Injection on Cerebral Ischemia.

Authors:  Yifei Qi; Yihuai Zou; Lin Chen; Jun Liu; Yingying Zhang; Zhong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-21       Impact factor: 2.629

6.  Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial.

Authors:  Bing Li; Yilong Wang; Jingjing Lu; Jun Liu; Ye Yuan; Yanan Yu; Pengqian Wang; Xingquan Zhao; Zhong Wang
Journal:  Trials       Date:  2015-12-09       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.